



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/635,342	08/06/2003	Nwe Y. BaMaung	6958.US.02	8084
23492	7590	07/21/2004	EXAMINER	
STEVEN F. WEINSTOCK ABBOTT LABORATORIES 100 ABBOTT PARK ROAD DEPT. 377/AP6A ABBOTT PARK, IL 60064-6008			REYES, HECTOR M	
		ART UNIT		PAPER NUMBER
		1625		
DATE MAILED: 07/21/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/635,342	BAMAUNG ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Hector M Reyes	1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### **Status**

1) Responsive to communication(s) filed on 20 January 2004.

2a) This action is FINAL.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### **Disposition of Claims**

4) Claim(s) 1-18 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) \_\_\_\_\_ is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) 1-18 are subject to restriction and/or election requirement.

#### **Application Papers**

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### **Priority under 35 U.S.C. § 119**

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### **Attachment(s)**

1) Notice of References Cited (PTO-892)      4) Interview Summary (PTO-413)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)      Paper No(s)/Mail Date. \_\_\_\_\_.  
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
 Paper No(s)/Mail Date \_\_\_\_\_.

5) Notice of Informal Patent Application (PTO-152)  
 6) Other: \_\_\_\_\_.

**RESTRICTION REQUEST**

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-15 and 16 in part, drawn to a series of nonheterocyclic acid or ester derivatives represented by formula I and pharmaceutical compositions comprising the same, as described in the said claims classified in classes 560 and 562, multiple subclasses. A single disclosed specie is hereby requested for search purpose.
- II. Claims 1-15 and 16 in part, drawn to a series of heterocyclic derivatives represented by formula I and pharmaceutical compositions comprising the same, as described in the said claims classified in classes 540-549, multiple subclasses. A single disclosed specie is hereby requested for search purpose.
- III. Claim 17, drawn to a method inhibiting angiogenesis in a mammal comprising any of the derivatives of formula I, classified in classes 424 and 514, multiple subclasses. ***This group may be subjected to further restriction. Election of a single specie is requested for search purpose.***
- IV. Claim 18, drawn to a method of treating any cancer type in a patient comprising any of the derivatives of formula I, classified in classes 424 and 514, multiple subclasses. ***This group may be subjected to further***

***restriction. Election of a single specie is requested for search purpose.***

Inventions II and I are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case they are different inventions because each one of the compounds embraced in the said groups are different in chemical structure, reactivity and physical and chemical characteristics and are not disclosed as used together. Indeed, each group is drawn to different subject matter to the extend that a given reference anticipating or suggesting any of the groups does not necessarily can be use to reject the other group within the meaning of 35 USC 102 or 35 USC 103.

Inventions IV and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions because each one of the claimed methods is intended to treat a different conditions.

The inventions are distinct, each from the other because of the following reasons: Inventions III, IV and II, I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case there are methods in the art

for the treatment of different cancers and for the inhibition of angiogenesis that do not require any of the compounds embraced in the instant claims.

Because these inventions are distinct for the reasons given above and the search required a given Group is not required for any of the other Groups, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

**CONCLUSION**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Hector M. Reyes, whose telephone number is (571)-272-0691. The examiner can normally be reached M-F on 9:00Am to 5:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ms. Rita Desai can be reached at 571-272-0684.

Hector M. Reyes, PhD JD  
Reg. # P-54846  
AU 1625  
July 19, 2004.

*R. Desai*  
7/19/04